BioSpace News Archive

Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the first quarter 2021 and provided an operational update.

MindMed, a leading clinical stage psychedelic medicine company, announces receipt of Type C Meeting Responses from FDA leading to the finalization of the Company’s clinical development approach for Project Lucy by selecting Generalized Anxiety Disorder as an initial indication.

Forian Inc. (NASDAQ: FORA), a provider of technology, analytics and data science driven solutions for the healthcare and cannabis industries, today announced results for its fiscal first quarter ended March 31, 2021.

-- Phase 3 Clinical Study of PL9643 in Patients with Dry Eye Disease Planned for Second Half Calendar 2021 -- Phase 2 Clinical Study of PL8177 in Patients with Ulcerative Colitis Planned for Second Half Calendar 2021 -- Vyleesi Gross Product Sales Up 89%, Net Revenue Up 154%, Prescriptions Increased 24% Compared to Prior Quarter -- $68.6 Million in Cash and Cash Equivalents as of March 31, 2021 -- Teleconference and Webcast to be Held Today at 11:00 AM ET

Q1 2021 Adjusted Total Revenue - $14.5 million - - Q1 2021 Adjusted EBITDA - $4.4 million - - Blexten Canadian Prescriptions Increased 22% Year-Over-Year - - Cambia Canadian Prescriptions Increased 9% Year-Over-Year - Miravo to Hold Virtual Annual Meeting May 17th at 9:00 a.m. ET

Titan Medical Inc. (Nasdaq: TMDI; TSX: TMD), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, announces financial results for the three months ended March 31, 2021.

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, today announced that it will host a webcast presentation on Wednesday, May 19, 2021 at 6:00 PM ET to discuss pharmacokinetic, safety, and preliminary efficacy data from the Phase 1

$8 million investment, including new building & FDA-approved vacuum plasma spray (VPS) equipment, enhances in-house coating and single-source orthopedic implant capabilities

Summit Therapeutics Inc. (NASDAQ: SMMT) today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2021.

Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, reported financial results for the quarter ended March 31, 2021 and provided key pipeline and business highlights.